The Swiss Biotech Association cordially invites you to join us at this prestigious launch event from 5:00–7:00 pm.
Embedded in Switzerland’s leading biotechnology conference – the Swiss Biotech Day – this evening will entertain you with an exclusive program celebrating the first laureates of Swiss Biotech Success Stories, accompanied by an apéro riche and plenty of room for networking.
Highlighting major industry achievements
On the occasion of its 20th anniversary, the Swiss Biotech Association is launching Swiss Biotech Success Stories to celebrate those who have made significant contributions to the industry. This recognition is dedicated to scientists, pioneers, entrepreneurs, innovators and supporters who led the way, opened the horizon and prepared the ground for lasting achievements. Swiss Biotech Success Stories accentuate past industry highlights and act as motivator for future achievements.
Laureates are individuals – or teams – who earned extraordinary merits for their scientific, medical and/or commercial achievements. The many different facets of success are reflected in the variety of their work. Swiss Biotech Success Stories will grow over time to encompass the biotech industry’s most remarkable accomplishments.
A jury of distinguished experts who observe the Biotech industry from different perspectives decides on the recognition as Swiss Biotech Success Story for significant achievements and admission to the Swiss Biotech hall of fame for multiple and sustainable successes.
Success stories contact & media info
Please contact us for further information: firstname.lastname@example.org
Luca Bolliger, president of the jury, vice president of Swiss Biotech Association, VP and director corporate licensing at Recordati.
Undergrad at ETH in Zürich with Master in Immunology. PhD at the Biocenter in Basel in biochemistry, and then Member of the Basel institute for immunology. Followed by Hoffmann-La Roche Ltd as a Global discovery portfolio manager. Further as Fundamental analyst at BT&T asset management, and as a freelance consultant. Established Biopolo Ticino where he also participated in the creation of the Swiss marketing platforms Swiss Biotech and Swiss Medtech. Then Director Business Development at Actelion, and NovImmune.
Patrick Aebischer, emeritus EPFL president, professor, serial entrepreneur.
MD (1980) and a Neuroscientist (1983) at the Universities of Geneva and Fribourg in Switzerland. Faculty positions at Brown University and the University of Lausanne prior to joining EPFL.He has received numerous honors, including the Robert Bing Prize of the Swiss Academy of Medicine and the Pfizer Foundation Prize for Clinical Neurosciences. He is a member of the scientific committee of the Italian Institute of Technology and a member of the Singapore Biomedical Sciences International Advisory Council. Prof. Aebischer is a member of the Board of Lonza, Nestlé and Logitech and a founder of three biotech companies. He chairs the Novartis Venture Fund and is a Senior Partner of NanoDimension-III.
Martine Clozel, co-founder and Chief Scientific Officer of Actelion and Idorsia.
Executive vice president, Chief Scientific Officer of Idorsia since 2017. Assistant professor neonatology. Scientific expert, leader of drug discovery projects, F. Hoffmann-La Roche. Founder and head of drug discovery, pharmacology & preclinical development, Actelion, 1997–2009. Chief Scientific Officer of Actelion 2009-2017.
Gabrielle Gache, president of Swiss Healthcare Licensing Group, head business development and licensing at Vifor Pharma.
Head Business Development and Licensing at Vifor Pharma in Switzerland, President Swiss Healthcare Licensing Group and member of the European Pharma Licensing Council, Gabrielle is passionate about health & well-being. She has more than 20 years of experience in the pharmaceutical industry and held various leading positions in finance, marketing and business development. Her experience at the medical research foundation completes this profile in the field of not-for-profit organization and tech transfers. Driven by an entrepreneurial spirit, she connects quickly and aims to establish long term partnering relationships where mutual respect matters.
Ulrich Geilinger, head private equity at HBM Partners
Over 25 years experience in the Venture Capital Industry. PhD ETH Zurich in Natural Sciences and Industrial Engineering. Previously in management functions at Innoventure, Credit Suisse, Apax and Vontobel. Board member of Westmed and Reha Technology.
Kaspar Hess, head of the entrepreneurial private banking at Mirabaud Basel
Head of entrepreneurs and executive section at Credit Suisse Basel until 2017. Sales manager for northwest and central Switzerland at Hotelplan, delegate of the executive board for sustainability at Hotelplan, 1998-2008.
Birgit Voigt, business journalist at NZZ am Sonntag
At NZZ am Sonntag, Birgit Voigt covers pharmaceutical as well as biotech companies and industry since 2002. Her education and positions include: business correspondent for “Cash” in California; knight fellowship in journalism, Stanford; head business section “Tages-Anzeiger”. She has a master in economics from the University of Zurich and in political science from Virginia Tech, USA.
Jürg Zürcher, partner, biotech/medtech leader GSA at Ernst & Young
Jürg Zürcher heads EY’s Biotechnology Sector in Europe, the Middle East, India and Africa. His main focus is the life sciences sector and he is also active in the venture capital business. Jürg Zürcher provided the Swiss Federal Government with a comprehensive analysis of the state of biotechnology in Switzerland. He also supported the introduction of the first Swiss Biotech Report in March 2004.
Thomas Staffelbach, Secretary of the jury, Senior consultant/owner of TS Kommunikation
Thomas Staffelbach is an experienced communications director, former head of communications and investor relations of several listed and private companies. Thomas is passionate about innovation and the people behind it. For almost 15 years, he has been advising biotech and pharmaceutical companies to position the medical and commercial potential of their innovations.